De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects
A total of 70 patients with HCC (mean age: 54.6 years, female/male: 12/58) received a liver
transplant and were included in the study. Immunosuppression included de novo sirolimus,
low-dose calcineurin inhibitor for 6 to 12 months, with short-course (3 months) or no
steroids.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Percentage of Participants Surviving at One and Four Years After Liver Transplant
Percent of Patients Surviving at One & Four years after Liver Transplant was calculated
1 & 4 years
No
Norman M Kneteman, MD
Principal Investigator
University of Alberta
Canada: Health Canada
#4279
NCT00328770
December 1996
March 2006
Name | Location |
---|